Saxenda

Adjunct to reduced-calorie diet & increased physical activity for chronic wt management in adults w/ initial BMI of ≥30 kg/m² or ≥27 kg/m² to <30 kg/m² in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (prediabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea. Adjunct to healthy nutrition & increased physical activity for wt management in adolescents ≥12 yr w/ obesity (BMI ≥30 kg/m²) or body wt >60 kg.

SC Adult & adolescent ≥12-18 yr Initially 0.6 mg once daily, should be increased to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk interval. Maintenance & max dose: 3 mg daily.

May be taken with or without food.

Hypersensitivity.

Not to be inj IV or IM. Not to be used as insulin substitute in patients w/ DM. Discontinue use if pancreatitis is suspected & if wt loss <5% after 12 wk use. Not recommended in patients w/ CHF NYHA class IV; inflammatory bowel disease, diabetic gastroparesis; patients treated w/ other wt management products; obesity secondary to endocrinological or eating disorders or treatment w/ wt gaining medicinal products. Cholelithiasis, cholecystitis; preexisting thyroid disease; increase in heart rate; dehydration. General anaesth- or deep sedation-related pulmonary aspiration. Increased risk of hypoglycaemia w/ insulin &/or sulfonylurea in patients w/ type 2 DM. Monitor heart rate at regular intervals. Avoid fluid depletion. Rotate inj site to reduce risk of inj site amyloid deposits. Not to be used in combination w/ another GLP-1 receptor agonist. May affect ability to drive & use machines. Mild or moderate hepatic impairment. Not recommended in severe hepatic & renal impairment (CrCl <30 mL/min) including ESRD. Not to be used during pregnancy & lactation. Clinically significant hypoglycaemia episodes in adolescents ≥12 yr. Childn <12 yr. Not recommended in elderly ≥75 yr.

Headache; nausea, vomiting, diarrhoea, constipation. Hypoglycaemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, upper abdominal pain, flatulence, eructation, abdominal distension; cholelithiasis; rash; inj site reactions, asthenia, fatigue; increased lipase & amylase.

Decreased C_max & delayed median T_max of paracetamol & atorvastatin. Increased C_max of griseofulvin. Reduced AUC & decreased C_max of digoxin & lisinopril. Lowered C_max of ethinylestradiol, levonorgestrel. Monitor INR w/ warfarin or other coumarin derivatives.

Anti-Obesity Agents / Antidiabetic Agents

A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.

B